Invivyd, Inc. IVVD
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026
Invivyd, Inc. (IVVD) is a healthcare company listed in the US with a market value of about $172M. In the twelve months to June 30, 2026 it had revenue of $58M and net income of -$107M, a net margin of -183.9%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -80%.
About Invivyd
Invivyd is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2021. It was profitable in 0 of the last 5 years in our data. Its share count rose by 59% over three years (dilution for shareholders). It spends 72% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 5 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Revenue | $58M | $53M | $25M | $0 | — | — |
| Net income | -$107M | -$52M | -$170M | -$199M | -$241M | -$227M |
| Free cash flow | -$110M | -$58M | -$171M | -$174M | -$222M | -$185M |
| EPS (diluted) | $-0.33 | $-0.30 | $-1.43 | $-1.81 | $-2.23 | $-5.32 |
| Net margin | -183.9% | -98.2% | -669.4% | — | — | — |
| ROIC | — | -18.1% | -201.7% | -93.8% | -54.9% | -32.1% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Invivyd pay a dividend?
Not currently.
Is Invivyd a good stock to buy?
We do not give buy or sell advice. Invivyd scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.